Essential Tremor Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036

Market Overview:

The 7 major essential tremor markets reached a value of USD 144.2 Million in 2025. Looking forward, IMARC Group expects the 7MM to reach USD 319.9 Million by ​2036​, exhibiting a growth rate (CAGR) of 7.29% during ​2026-2036​.

The essential tremor market has been comprehensively analyzed in IMARC's new report titled "Essential Tremor Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook ​2026-2036​". Essential tremor is a neurological illness marked by uncontrolled, rhythmic shaking, most commonly in the hands, but it can also affect the head, voice, or legs. It is the most prevalent movement disorder and usually worsens with time. Unlike Parkinson's disease tremors, essential tremors typically occur during voluntary movements, such as eating, writing, or holding items, rather than at rest. Essential tremor almost always affects both sides of the body but often affects one side more than the other. Symptoms may include shaking hands, problems in the gait and balance, a quivering voice, difficulty performing exact activities, or nodding. Emotional stress, exhaustion, and caffeine can all aggravate tremors. Essential tremor diagnosis is primarily based on a neurological examination and a review of the patient's history, including family history and symptoms. The healthcare provider may also utilize imaging techniques, like computed tomography scans and magnetic resonance imaging to rule out structural problems in the brain, such as tumors or strokes, that could cause tremor.

To get more information on this market, Request Sample

The escalating cases of genetic mutations, which can alter the normal function of genes involved in motor control and cerebellar activity, are primarily driving the essential tremor market. In addition to this, the inflating utilization of beta-adrenergic blockers, which works by blocking neurotransmitters to reduce the speed and amplitude of rapid muscle movements associated with tremor, is also creating a positive outlook for the market. Moreover, the widespread adoption of botulinum toxin on account of its numerous advantages, such as targeted tremor control, improved quality of life, and minimal systemic side effects, is further bolstering the market growth. Apart from this, the rising usage of orthotic devices that can effectively reduce tremors caused by essential tremor by physically dampening movement or using other mechanical or electrical mechanisms, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of deep brain stimulation (DBS) procedure, since it involves implanting electrodes in specific areas of the brain and using electrical stimulation to disrupt abnormal signals that cause tremors, is expected to drive the essential tremor market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the essential tremor market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for essential tremor and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the essential tremor market in any manner.

Recent Developments:

• In February 2025, Praxis Precision Medicines provided an update on the interim analysis for Study 1 of the Essential3 program of ulixacaltamide in essential tremor.
• In June 2024, Jazz Pharmaceuticals revealed top-line findings of suvecaltamide (JZP385), a novel, highly selective and state-dependent T-type calcium channel modulator, from the Phase 2b trial assessing efficacy and safety in adult patients suffering from essential tremor.

Drugs:

Inderal (Propranolol) is a non-selective beta-adrenergic receptor blocker. By blocking beta-adrenergic receptors, this drug reduces the impact of adrenaline (epinephrine) and noradrenaline (norepinephrine), which are neurotransmitters involved in the sympathetic nervous system. This, in turn, leads to a decrease in the sympathetic nervous system's overall activity, which can contribute to tremors. Additionally, propranolol's blockage of beta-2 receptors, especially in deep muscle spindles, may directly reduce tremor.

Ulixacaltamide, developed by Praxis Precision Medicines, is an investigational oral therapy for essential tremor that selectively inhibits T-type calcium channels. These channels are integral to the cerebello-thalamo-cortical circuit, a neural pathway involved in coordinating movement. In essential tremor, overactivity in this circuit leads to abnormal neuronal burst firing, resulting in involuntary tremors. By targeting these specific channels, ulixacaltamide aims to normalize neuronal firing patterns, thereby reducing tremor severity.

Suvecaltamide (JZP385) is an investigational drug from Jazz Pharmaceuticals, which works by selectively modulating T-type calcium channels (Cav3). These channels play a role in the brain's control of muscle movement. Suvecaltamide preferentially binds to stabilize a specific conformation of the channel, reducing its activity. This mechanism is thought to help reduce tremors in conditions like essential tremor.

Time Period of the Study

• Base Year: 2025
• Historical Period: ​2020-2025​
• Market Forecast: ​2026-2036​

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the essential tremor market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the essential tremor market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape

This report also provides a detailed analysis of the current essential tremor marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

• How has the essential tremor market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2025 and how are they expected to perform till 2036?
• What was the country-wise size of the essential tremor across the seven major markets in 2025 and what will it look like in 2036?
• What is the growth rate of the essential tremor across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​2020-2036​) of essential tremor across the seven major markets?
• What is the number of prevalent cases (​2020-2036​) of essential tremor by age across the seven major markets?
• What is the number of prevalent cases (​2020-2036​) of essential tremor by gender across the seven major markets?
• What is the number of prevalent cases (​2020-2036​) of essential tremor by type across the seven major markets?
• How many patients are diagnosed (​2020-2036​) with essential tremor across the seven major markets?
• What is the size of the essential tremor patient pool (​2020-2025​) across the seven major markets?
• What would be the forecasted patient pool (​2026-2036​) across the seven major markets?
• What are the key factors driving the epidemiological trend essential tremor of?
• What will be the growth rate of patients across the seven major markets?

Essential Tremor: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for essential tremor drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the essential tremor market?
• What are the key regulatory events related to the essential tremor market?
• What is the structure of clinical trial landscape by status related to the essential tremor market?
• What is the structure of clinical trial landscape by phase related to the essential tremor market?
• What is the structure of clinical trial landscape by route of administration related to the essential tremor market?